RVNC - Revance Therapeutics expects to achieve positive adj EBITDA in 2025
2024-01-08 11:47:12 ET
More on Revance Therapeutics
- Revance Therapeutics: Not Even Daxxify Can Treat Investor Frown Lines
- Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Call Transcript
- Public Citizen petitions FDA for stricter warnings against Botox, similar drugs
- Needham says Abbvie's Botox sales results good news for Evolus, Revance
- Seeking Alpha’s Quant Rating on Revance Therapeutics
For further details see:
Revance Therapeutics expects to achieve positive adj EBITDA in 2025